Drug Profile
Research programme: farnesoid X receptor modulators - Phenex/Gilead Sciences
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Phenex Pharmaceuticals
- Class Small molecules
- Mechanism of Action Farnesoid X-activated receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Metabolic syndrome; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Metabolic-syndrome in Germany
- 04 Nov 2017 No recent reports of development identified for preclinical development in Non-alcoholic-fatty-liver-disease in Germany
- 04 Nov 2017 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in Germany